European Archives - Page 578 of 1122 - European Medical Journal

Clarity on Cannabinoid-Based Products in Medicine

This document aims to provide an overview of the clinical and regulatory challenges faced in the use of cannabinoid-based products in medicine, without becoming a comprehensive humanity review of the literature on the medical possibilities of cannabinoids.

EMJ Oncology 9 [Supplement 4] 2021 Feature Image

EMJ Oncology 9 [Supplement 4] 2021

OVARIAN cancer is the seventh most commonly diagnosed malignancy among women worldwide, and the gynaecologic cancer with the…

EMJ Oncology 9 [Supplement 4] 2021 Feature Image

PARP Inhibitors in Advanced Ovarian Cancer: A Review of Long-term Efficacy and Survival Rates

This article discusses the results published in 2020 and early 2021 from key clinical trials of PARP inhibitors in patients with advanced ovarian cancer in terms of long-term efficacy and survival rates.

Talking to Denise Dewar

Denise Dewar, Digital Hub Director, Europe, Japan and Canada, GSK, discusses digital transformation and swapping whisky for pharma.

Doxycycline Antibiotic Shows Promise Treating TB

Hopeful researchers have discovered use of the common antibiotic doxycycline, in combination with TB drug treatment, effective in reducing these lung cavities and accelerating markers of lung recovery.

Asthma Risk Identified Among Infants with Lung Infection

Research conducted at Massachusetts General Hospital (MGH) has uncovered four subtypes of infection, caused by the bronchiolitis respiratory syncytial virus (RSV), one of which is linked with higher asthma risk.

EMJ Podcast: Neuroscience meets NASA

This week, Jonathan sits down with Professor Babak Kateb, Chairman and CEO, Society for Brain Mapping and Therapeutics, to discuss the potential of cross-discipline collaboration, and reveal what he thinks will be the spaces to watch in neurology and research.

Pulling away from push marketing

While pharmaceutical marketers used to rely heavily on push marketing, since the pandemic, a call to move to pull advertising has prevailed. How can pharma further engage the medical affairs function to draw in doctors with tailored, scientific content that is targeted and trustworthy?

Preparing for the next pandemic

The pharmaceutical industry could have been better prepared for the COVID-19 pandemic. What did they learn that will help them respond better in the future?

A debate on digital transformation

In this roundtable, three thought leaders detail the barriers in the way of digital transformation and outline their vision for the future.